Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Lexicon Pharmaceuticals (Nasdaq: LXRX) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Lexicon's business and see what CAPS investors are saying about the stock right now.

Lexicon facts

Headquarters (founded) The Woodlands, Texas (1995)
Market Cap $1.4 billion
Industry Biotechnology
Trailing-12-Month Revenue $1.6 million
Management Co-founder/CEO Arthur Sands
Co-founder/Chief Scientific Officer Brian Zambrowicz
Return on Equity (average, past 3 years) (41.8%)
Cash/Debt $253.2 million / $24.5 million
Competitors Athersys
Exelixis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 20% of the 64 All-Star members who have rated Lexicon believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, zzlangerhans, touched on the stock's seemingly unsustainable valuation:

In late June Lexicon announced positive results from the phase IIb trial of glucose transporter inhibitor LX4211. I don't really have a complaint about the data. It looks good. But the study doesn't clearly establish where LX4211 might fit into diabetes management, a rapidly evolving field with numerous proprietary and generic therapies available. I think when Lexicon has a positive catalyst, investors sometimes forget about their enormous 480M share count and concurrent bloated market cap. When the share price hit [$3.20], the market cap approached [$1.5B]. That's quite a chunk of change for LX4211 and some other less inspiring pipeline candidates, and a hard level of interest to maintain in the years ahead before LX4211 can be commercialized.

If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Exelixis. Motley Fool newsletter services have recommended buying shares of Exelixis. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.